As part of a commitment to providing optimal therapy, patients who participate in the trial will receive an implantable cardioverter defibrillator (ICD) with Home Monitoring. These devices ensure optimal standard of care for patients with severe cardiac conditions. BIOTRONIK Home Monitoring offers the most advanced remote monitoring for cardiac patients employing cellular technology in the third generation. The BIOTRONIK Home Monitoring system safely reduces the need for conventional in-office visits, while improving follow-up adherence, and enables earlier evaluation of clinically relevant cardiovascular events.
“This partnership with Cardio3 BioSciences, highlights the quality of the BIOTRONIK Home Monitoring system and also provides BIOTRONIK with the opportunity to be directly involved in one of the most innovative areas of medicine. Longer term, what we learn through the trial will allow us to evaluate the potential to combine our innovative device technology with complementary approaches such as stem cell therapy so as to offer outstanding solutions to help to restore and secure the patient’s quality of life in a lasting way,” remarked Marlou Janssen, Global Vice President Marketing and Sales at BIOTRONIK GmbH & Co KG.
Dr Christian Homsy, CEO of Cardio3 BioSciences, commenting on announcement, said: “We are delighted to announce that we have partnered with BIOTRONIK to provide ICD technology for the C-Cure trial. In developing our stem cell technologies we are driven by a desire to provide the best possible quality of treatment to patients with heart disease and this is carried through in choosing partners and suppliers for our trial. We believe that by working with BIOTRONIK we are giving patients access to the highest quality monitoring technology. We look forward to further progressing the trial which for the first time will evaluate in patients whether ‘cardiopoietic’ cells, the active ingredient of C-Cure, can be used to re-generate heart muscle damaged by infarction. If C-Cure can achieve this goal, it will clearly be a major advance in the treatment of heart failure, a very common condition where current therapy does not address the underlying cause of the disease.”
